Silvia Mariel Ferrucci, MD, is an adjunct professor of dermatology at the University of Milan and the head of the the Allergology Dermatology Service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.

Silvia Mariel Ferrucci, MD

New real-world 3-year data from the multinational GLOBOSTAD study suggest that dupilumab therapy (Dupixent) demonstrates sustained efficacy and safety in patients with 

These findings resulted from a poster presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 in Denver, Colorado. These real-world insights in the overall population treated with dupilumab were discussed in a new interview with Silvia Mariel Ferrucci, MD, an adjunct professor of dermatology at the University of Milan and head of the Allergology Dermatology Service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.

 highlights Ferrucci’s responses to inquiries about her team’s findings and their significance in the 2026 treatment landscape:

Can you give an overview of the GLOBOSTAD study and what makes this dataset particularly valuable for understanding long-term outcomes with dupilumab?

GLOBOSTAD is a global study to evaluate the impact of dupilumab (or Dupixent) on disease outcomes in clinical practice. Observational studies like this provide further evidence about the safety and efficacy of approved treatments, like Dupixent, in real-world settings and also allow us to evaluate treatment effect in a large, diverse cohort of patients over time. Long-term evaluation of atopic dermatitis is particularly important as it’s a chronic disease where many factors, including environmental changes, can instigate flare-ups throughout and over the years.

What was the overall design of this study, and how does its real-world, observational nature shape how we should interpret the findings?

The study enrolled patients 12 years of age and older with moderate-to-severe atopic dermatitis who were receiving Dupixent based on country-specific prescribing information. Outcomes were assessed at baseline, 3 months, 6 months and then every 6 months up to 3 years for this interim analysis. The study is ongoing and will evaluate patients for 5 years.

The study adds real-world evidence that further supports the established ability of Dupixent to improve signs and symptoms of atopic dermatitis, but because GLOBOSTAD is not a randomized, placebo-controlled trial, definitive conclusions about safety and efficacy cannot be made based on these results.

At the 3-year mark, what stood out most to you in terms of sustained effectiveness for patients with atopic dermatitis?

In a diverse, real-world population, Dupixent showed sustained effectiveness on measures of disease severity as well as patient-reported symptom severity, itch and health-related quality of life over 3 years compared to baseline. Importantly, the mean values for disease severity, patient-reported symptoms and itch were in the mild/no disease range and patients reported no-to-small effect on health-related quality of life at 3 years of Dupixent treatment.

How did the safety profile of dupilumab evolve over time in this real-world population?

 The safety profile was consistent with the known safety profile of Dupixent. Adverse events occurring in at least 5% of patients included allergic conjunctivitis, COVID-19 and conjunctivitis, with most having resolved or were resolving at the end of the observation period.

 Based on these long-term data, what do you think are the key clinical implications for dermatologists managing patients with moderate-to-severe atopic dermatitis?

Dupixent is already approved for eligible patients with atopic dermatitis in several countries around the world, so long-term, real-world analyses like these provide further evidence about the value Dupixent can bring to reducing disease burden for atopic dermatitis patients in clinical practice. Additionally, GLOBOSTAD will collect data about the impact of Dupixent on outcomes related to coexisting type 2 diseases, like asthma, which could also help inform clinical decision making for patients with comorbid conditions.

The quotes used in this Q&A interview summary were edited for clarity.

Ferrucci has served as a principal investigator in clinical trials for AbbVie, Almirall, Galderma, Leo Pharma, Sanofi, Amgen, and Novartis, Bayer, and received honoraria for lectures for Novartis and Menarini.

Ferrucci S, et al. Dupilumab Shows Sustained Effectiveness and Safety in Patients with Atopic Dermatitis: Real-World Insights from the Overall Population 3 Years into the GLOBOSTAD Multinational Prospective Observational Study. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Smith T. Dupilumab Treatment of Atopic Dermatitis Safe for Up to 5 Years in Children, Adults. HCPLive. December 12, 2024. Accessed April 17, 2026. 

https://www.hcplive.com/view/dupilumab-treatment-atopic-dermatitis-safe-up-to-5-years-children-adults

Articles

Three-year interim real-world data from the multinational prospective observational GLOBOSTAD cohort support sustained dupilumab effectiveness and a safety profile consistent with established experience in patients ≥12 years with moderate-to-severe atopic dermatitis. Serial assessments from baseline through 36 months showed durable improvements in clinician-assessed severity, patient-reported symptom burden, pruritus, and health-related quality of life, with mean outcomes in the mild/no-disease range at year 3. Common adverse events (≥5%) included conjunctivitis/allergic conjunctivitis and COVID-19, largely resolving by observation end.

In this Q&A interview, Ferrucci highlights key real-world findings from the GLOBOSTAD on the safety and efficacy of dupilumab (Dupixent) in atopic dermatitis.